TransMedics Group, Inc. (NASDAQ:TMDX) Receives $122.70 Consensus PT from Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $122.70.

TMDX has been the topic of several analyst reports. Robert W. Baird reduced their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Canaccord Genuity Group cut their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Finally, Piper Sandler lowered their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th.

Insider Activity at TransMedics Group

In related news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Atlas Capital Advisors Inc. bought a new stake in TransMedics Group during the fourth quarter worth $31,000. Hager Investment Management Services LLC purchased a new position in TransMedics Group during the 4th quarter worth $33,000. Sachetta LLC bought a new stake in shares of TransMedics Group in the 4th quarter worth $40,000. AlphaQuest LLC purchased a new stake in shares of TransMedics Group in the fourth quarter valued at about $52,000. Finally, Quarry LP lifted its position in shares of TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Up 1.3 %

NASDAQ TMDX opened at $72.18 on Wednesday. The firm has a market capitalization of $2.42 billion, a PE ratio of 76.79 and a beta of 2.12. The business’s 50-day moving average price is $65.79 and its two-hundred day moving average price is $107.46. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $177.37.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.